Dosing of antibiotics in critically Ill patients undergoing renal replacement therapy

Current Pharmaceutical Biotechnology

Volumn 12, Issue 12, 2011, Pages 2015-2019

  Kielstein, Jan T ^a   Burkhardt, Olaf ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Clearance; Critically ill; Dialysis; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; DAPTOMYCIN; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; VANCOMYCIN; VORICONAZOLE;

ACUTE KIDNEY FAILURE; ANTIBIOTIC THERAPY; ARTICLE; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DOSE CALCULATION; DRUG METABOLISM; EXTENDED DIALYSIS; HUMAN; INTENSIVE CARE; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; SURVIVAL;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; HUMANS; RENAL REPLACEMENT THERAPY;

EID: 84855231250     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798808275     Document Type: Article

References (54)

1. Hospitalization discharge diagnoses for kidney disease-United States, 1980-2005. MMWR Morb. Mortal. Wkly Rep., 2008, 57, 309-312.
2. Kumar, A.; Zarychanski, R.; Light, B.; Parrillo, J.; Maki, D.; Simon, D.; Laporta, D.; Lapinsky, S.; Ellis, P.; Mirzanejad, Y.; Martinka, G.; Keenan, S.; Wood, G.; Arabi, Y.; Feinstein, D.; Kumar, A.; Dodek, P.; Kravetsky, L.; Doucette, S. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock, a propensity-matched analysis. Crit Care Med., 2010, 38, 1773-1785.
3. Uchino, S.; Kellum, J.A.; Bellomo, R.; Doig, G.S.; Morimatsu, H.; Morgera, S.; Schetz, M.; Tan, I.; Bouman, C.; Macedo, E.; Gibney, N.; Tolwani, A.; Ronco, C; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients, a multinational, multicenter study. JAMA, 2005, 294, 813-818.
4. Kielstein, J.T.; Kretschmer, U.; Ernst, T.; Hafer, C.; Bahr, M.J.; Haller, H.; Fliser, D. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients, a randomized controlled study. Am. J. Kidney Dis., 2004, 43, 342-349.
5. Mueller, B.A.; Paskom D.A.; Sowinski, K.M. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs, 2003, 27, 808-814.
6. Ronco, C.; Bellomo, R.; Homel, P.; Brendolan, A.; Dan, M.; Piccinni, P.; La Greca, G. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure, a prospective randomised trial. Lancet, 2000, 356, 26-30.
7. Kielstein, J.T.; Burkhardt, O.; Bode-Boeger, S.M. Dose matters, dose of antibiotics in the critically ill patient depends on the dose of renal replacement therapy. Crit. Care Med., 2009, 37, 2491-2492.
8. Fiaccadori, E.; Parenti, E.; Maggiore, U. Nutritional support in acute kidney injury. J. Nephrol., 2008, 21, 645-656.
9. Bellomo, R.; Cass, A.; Cole, L.; Finfer, S.; Gallagher, M.; Lo, S.; McArthur, C.; McGuinness, S.; Myburgh, J.; Norton, R.; Scheinkestel, C.; Su, S. Intensity of continuous renal-replacement therapy in critically ill patients. N. Engl. J. Med., 2009, 361, 1627-1638.
10. Faulhaber-Walter, R.; Hafer, C.; Jahr, N.; Vahlbruch, J.; Hoy, L.; Haller, H.; Fliser, D.; Kielstein, J.T, The Hannover Dialysis Outcome study, comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol. Dial. Transplant, 2009, 24, 2179-2186.
11. Palevsky, P.M.; Zhang, J.H.; O'Connor, T.Z. Intensity of renal support in critically ill patients with acute kidney injury. N. Engl. J. Med., 2008, 359, 7-20.
12. Jun, M.; Heerspink, H.J.; Ninomiya, T.; Gallagher, M.; Bellomo, R.; Myburgh, J.; Finfer, S.; Palevsky, P.M.; Kellum, J.A.; Perkovic, V.; Cass, A. Intensities of renal replacement therapy in acute kid ney injury, a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol., 2010, 5, 956-963.
13. Kumar, V.A.; Yeun, J.Y.; Depner, T.A.; Don, B.R. Extended daily dialysis vs. continuous hemodialysis for ICU patients with acute renal failure, a two-year single center report. Int. J. Artif. Organs, 2004, 27, 371-379.
14. Marshall, M.R.; Ma, T.; Galler, D.; Rankin, A.P.; Williams, A.B. Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy, towards an adequate therapy. Nephrol. Dial Transplant, 2004, 19, 877-884.
15. Burkhardt, O.; Hafer, C.; Langhoff, A.; Kaever, V.; Kumar, V.; Welte, T.; Haller, H.; Fliser, D.; Kielstein, J.T. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol. Dial Transplant, 2009, 24, 267-271.
16. Czock, D.; Husig-Linde, C.; Langhoff, A.; Schöpke, T.; Hafer, C.; de Groot, K.; Swoboda, S.; Kuse, E.; Haller, H.; Fliser, D.; Keller, F.; Kielstein, J.T. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin. J. Am. Soc. Nephrol., 2006, 1, 1263-1268,
17. Kielstein, J.T.; Czock, D.; Schopke, T.; Hafer, C.; Bode-Böger, S.M.; Kuse, E.; Keller, F.; Fliser, D. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit. Care Med., 2006, 34, 51-56.
18. Roberts, J.A.; Lipman, J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med., 2009, 37, 840-851.
19. Burkhardt, O.; Thon, S.; Burhenne, J; Welte, T.; Kielstein, J.T. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. Int. J. Antimicrob. Agents, 2010, 36, 93-94
20. Ricci, Z.; Ronco, C.; D'Amico, G.; De Felice, R.; Rossi, S.; Bolgan, I.; Bonello, M.; Zamperetti, N.; Petras, D.; Salvatori, G.; Dan, M.; Piccinni, P. Practice patterns in the management of acute renal failure in the critically ill patient, an international survey. Nephrol. Dial Transplant, 2006, 21, 690-696.
21. Stevenson, J.M.; Patel, J.H.; Churchwell, M.D.; Vilay, A.M.; Depestel, D.D.; Sörgel, F.; Kinzig, M.; Jakob, V.; Mueller, B.A. Ertapenem clearance during modeled continuous renal replacement therapy. Int. J. Artif. Organs, 2008, 31, 1027-1034.
22. Ahern, J.W.; Lai, C.; Rebuck, J.A.; Possidente, C.J.; Weidner, M., Experience with vancomycin in patients receiving slow lowefficiency dialysis. Hospital Pharmacy, 2004, 39, 138-143.
23. Tian, Q.; Gomersall, C.D.; Ip, M.; Tan, P.E.; Joynt, G.M.; Choi, G.Y. Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob. Agents Chemother., 2008, 52, 1009-1013.
24. Kielstein, J.T.; Lorenzen, J.; Kaever, V.; Burhenne, H.; Broll, M.; Hafer, C.; Burkhardt, O. Risk of underdosing of ampicillin/ sulbactam in patients with acute kidney injury undergoing extended daily dialysis--a single case. Nephrol. Dial Transplant, 2009, 24, 2283-2285.
25. Isla, A.; Gascon, A.R.; Maynar, J.; Arzuaga, A.; Toral, D.; Pedraz, J.L. Cefepime and continuous renal replacement therapy (CRRT), in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Clin. Ther., 2005, 27, 599-608.
26. Malone, R.S.; Fish, D.N.; Abraham, E.; Teitelbaum, I. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob. Agents Chemother., 2001, 45, 3148-3155.
27. Isla, A.; Gascon, A.R.; Maynar, J.; Arzuaga, A.; Sánchez-Izquierdo, J.A.; Pedraz, J.L. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy, 2007, 53, 194-201.
28. Matzke, G.R.; Frye, R.F.; Joy, M.S.; Palevsky, P.M. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob. Agents Chemother., 2000, 44, 1639-1644.
29. Moriyama, B.; Henning, S.A.; Neuhauser, M.M.; Danner, R.L.; Walsh, T.J. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. Ann. Pharmacother., 2009, 43, 1324-1337.
30. Traunmuller, F.; Schenk, P.; Mittermeyer, C.; Thalhammer-Scherrer, R.; Ratheiser, K.; Thalhammer, F. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J. Antimicrob. Chemother., 2002, 49, 129-134.
31. Malone, R.S.; Fish, D.N.; Abraham, E.; Teitelbaum, I. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob. Agents Chemother., 2001, 45, 2949-2954.
32. Wagner, C.C.; Steiner, I.; Zeitlinger, M. Daptomycin elimination by CVVH in vitro, evaluation of factors influencing sieving and membrane adsorption. Int. J. Clin. Pharmacol. Ther., 2009, 47, 178-186.
33. Kielstein, J.T.; Eugbers, C.; Bode-Boeger, S.M.; Martens-Lobenhoffer, J.; Haller, H.; Joukhadar, C.; Traunmüller, F.; Knitsch, W.; Hafer, C.; Burkhardt, O. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. Nephrol. Dial Transplant, 2010, 25, 1537-1541.
34. Gattringer, R.; Meyer, B.; Heinz, G.; Guttmann, C.; Zeitlinger, M.; Joukhadar, C.; Dittrich, P.; Thalhammer, F. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. J. Antimicrob. Chemother., 2006, 58, 367-371.
35. Manley, H.J.; Bailie, G.R.; McClaran, M.L.; Bender, W.L. Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int., 2003, 63, 1072-1078.
36. Fish, D.N.; Teitelbaum, I.; Abraham, E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob. Agents Chemother., 2005, 49, 2421-2428.
37. Bellmann, R.; Egger, P.; Gritsch, W.; Bellmann-Weiler, R.; Joannidis, M.; Dunzendorfer, S.; Wiedermann, C.J. Elimination of levofloxacin in critically ill patients with renal failure, influence of continuous veno-venous hemofiltration. Int. J. Clin. Pharmacol. Ther., 2002, 40, 142-149.
38. Choi, G.; Gomersall, C.D.; Lipman, J.; Wong, A.; Joynt, G.M.; Leung, P.; Ramsay, S.J.; Ho, O.M. The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration an in vitro study of levofloxacin. Int. J. Antimicrob. Agents, 2004, 24, 468-472.
39. Guenter, S.G.; Iven, H.; Boos, C.; Bruch, H.P.; Muhl, E. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Pharmacotherapy, 2002, 22, 175-183.
40. Traunmuller, F.; Thalhammer-Scherrer, R.; Locker, G.J.; Losert, H.; Schmid, R.; Staudinger, T.; Thalhammer, F. Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. J. Antimicrob, Chemother., 2001, 47, 229-231.
41. Meyer, B.; Kornek, G.V.; Nikfardjam, M.; Karth GD.; Heinz, G.; Locker, G.J.; Jaeger, W.; Thalhammer, F. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J. Antimicrob. Chemother., 2005, 56, 172-179.
42. Pea, F.; Viale, P.; Lugano, M.; Pavan, F.; Scudeller, L.; Della Rocca, G.; Furlanut, M. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration, a report of 2 cases. Am. J. Kidney Dis., 2004, 44, 1097-1102.
43. Fiaccadori, E.; Maggiore, U.; Rotelli, C.; Giacosa, R.; Parenti, E.; Picetti, E.; Manini, P.; Andreoli, R.; Cabassi, A. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol. Dial Transplant, 2006, 21, 1402-1406.
44. Fiaccadori, E.; Maggiore, U.; Rotelli, C.; Giacosa, R.; Parenti, E.; Picetti, E.; Sagripanti, S.; Manini, P.; Andreoli, R.; Cabassi, A. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit. Care Med., 2004, 32, 2437-2442.
45. Swoboda, S.; Ober, M.C.; Lichtenstern, C.; Saleh, S.; Schwenger, V.; Sonntag, H.G.; Haefeli, W.E.; Hempel, G.; Hoppe-Tichy, T.; Weigand, M.A Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur. J. Clin. Pharmacol., 2010, 66, 291-298.
46. Kuti, J.L.; Nicolau, D.P. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. Chemotherapy, 2005, 51, 211-216.
47. Thalhammer, F.; Schenk, P.; Burgmann, H.; El Menyawi, I.; Hollenstein, U.M.; Rosenkranz, A.R.; Sunder-Plassmann, G.; Breyer, S.; Ratheiser, K. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob. Agents Chemother., 1998, 42, 2417-2420.
48. Valtonen, M.; Tiula, E.; Backman, J.T.; Neuvonen, P.J. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J. Antimicrob. Chemother., 2000, 45, 701-704.
49. Deshpande, P.; Chen, J.; Gofran, A.; Murea, M.; Golestaneh, L. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED). Nephrol. Dial Transplant, 2010, 25, 2632-2636.
50. Fuhrmann, V.; Schenk, P.; Jaeger, W.; Ahmed, S.; Thalhammer, F. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J. Antimicrob. Chemother., 2004, 54, 780-784.
51. Arzuaga, A.; Isla, A.; Gascon, A.R.; Maynar J.; Corral, E.; Pedraz, J.L. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters, evaluation of the sieving coefficient. Blood Purif., 2006, 24,347-354.
52. Valtonen, M.; Tiula, E.; Takkunen, O.; Backman, J.T.; Neuvonen, P.J. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J. Antimicrob. Chemother., 2001, 48, 881-885.
53. DelDot, M.E.; Lipman, J.; Tett, S.E. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br. J. Clin. Pharmacol., 2004, 58, 259-268.
54. Golestaneh, L.; Gofran, A.; Mokrzycki, M.H.; Chen, J.L. Removal of vancomycin in sustained low-efficiency dialysis (SLED), a need for better surveillance and dosing. Clin. Nephrol., 2009, 72, 286-291.